NASD · Healthcare · Biotechnology · USA
Tango Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Tango Therapeutics develops targeted oncology medicines by identifying novel targets and designing small molecules tailored to cancer cells with specific genetic alterations. The company is advancing clinical development of two PRMT5 inhibitors: vopimetostat for non-CNS tumors both alone and paired with RAS inhibitors, and TNG456, a brain-penetrant variant for CNS cancers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Tango Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on TNGX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.